# EDGAR Filing Document

**Accession Number:** 0001781983
**File Stem:** 0001104659-25-124218
**Filing Date:** 2025-12
**Character Count:** 2188
**Document Hash:** 18cea5b6159500a6f5130cec70a0ddff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-124218.hdr.sgml**: 20260701

**ACCESSION NUMBER**: 0001104659-25-124218

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aprea Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001781983
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902
- **BUSINESS PHONE:** 215-948-4119

**MAIL ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902

December 23, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

Attention: Chris Edwards

---

| | |
|:---|:---|
| **Re:** | **Aprea Therapeutics, Inc.** |
|  | **Registration Statement on Form S-3**<br> **Filed December 19, 2025**<br> **File No. 333-292286**<br> **Acceleration Request**<br> **Requested Date: December 29, 2025**<br> **Requested Time: 4:00 P.M. Eastern Time**  |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the "***Registrant***") hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-292286) (the "***Registration Statement***") be declared effective on the "Requested Date" at the "Requested Time" set forth above, or as soon as practicable thereafter.

We request that we be notified of the effectiveness of the Registration Statement by telephone to Patrick O'Malley of DLA Piper LLP (US) at 858.677.1471. Thank you for your assistance.

---

| |
|:---|
| Very truly yours, |
| **Aprea Therapeutics, Inc.** |
| /s/ John Hamill |
| John Hamill |
| Chief Financial Officer |

---

cc: Oren Gilad (Chief Executive Officer; Aprea Therapeutics, Inc.) Patrick O'Malley (DLA Piper LLP (US))